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ots  of steroids  and vitamins,  tons  of complications.





























plication of vitamin D intake.8 Usually results from doses thatomplications of  performance-
ontones  de  esteroides  y  vitamina
ipercalcemia  y  nefrocalcinosis  com
e  los  fármacos  para  mejorar  el  ren
ear Editor,
hronic hypercalcemia can be an important complica-
on of anabolic steroid and vitamin supplement abuse.
e report the case of a 30-year-old bodybuilder that for
ore  than 4 years used injectable anabolic-androgenic ste-
ids (AAS) and one veterinary polyvitamin formulation
ith vitamin A (2,100,000 IU), D (ergocalciferol: 60,000 IU),
d E (55 IU) on a monthly basis. He also reported self-
jecting mineral oil intramuscularly for esthetic purposes
r more  than 2 years. He presented to the emergency
om with an acute, severe epigastric pain, associated
ith nausea and vomiting. Laboratory evaluation (Table 1)
emonstrated an elevated amylase 2500 IU/L (50–160 IU/L);
pase of 612 IU/L (0–75 IU/L); a corrected serum calcium of
.5 mg/dL (8.5–10.5 mg/dL); PTH of 73.2 pg/mL (15–68.3 pg/mL)
d 25(OH)D of 65.1 ng/mL (30–100 ng/mL). Serum creatinine
as 1.2 mg/dL (0.6–1.2 mg/dL). Abdominal ultrasound showed
diffusely edematous pancreas, bilateral ureterolithiasis and
ephrocalcinosis. A high-resolution CT of the chest and abdo-
en  was performed and revealed absence of granulomas and
mphadenopathies. He had a tormented clinical course, with
ute kidney injury (attributed to volume depletion and renal
soconstriction in the setting of hypercalcemia) without the
eed of hemodialysis; protracted vomiting that lead to a lapa-
scopic duodenum–jejunum anastomosis with improvementf complains and multiple infectious complications. Serum
lcium and PTH returned to normal levels (9 mg/dL and
 pg/mL, respectively) after vitamin D discontinuation, vigo-
us venous hydration with 0.9% saline infusion and therapy
ith furosemide and corticosteroids. After more  than 60 days









toneladas  de  complicaciones.
 complicaciones  importantes
miento
With the desire to improve performance, some athletes
r amateurs use performance-enhancing drugs. The wides-
read use of these substances without medical prescription
r clinical follow-up can lead to serious health problems as
escribed on several reports.1–3 We  believe that the main
inical features seen in this patient are due to chronic hyper-
lcemia due to multiple substance abuse and parafﬁnomas.
he association between focal segmental glomerulosclerosis
d anabolic steroids abuse may be explained by increase
 lean body mass and potential direct nephrotoxic effects
f anabolic steroids.1 Furthermore, this drug modulates ste-
id hydroxylase activity predisposing to hypercalcemia.4 The
sociation of vitamin A toxicity and hypercalcemia is rare
ut well recognized. It is attributed to a direct effect on
one (activation of bone reabsorption with increased osteo-
ast activity),5 on the parathyroid, or in both.6 According to
hertow et al., vitamin A stimulate PTH secretion in bovine
arathyroid tissue and in men.6,7 The minimum dose of vita-
in  A required to produce hypercalcemia cannot be stated
ith certainty; toxicity has been described from doses ranging
om 50,000 to 500,000 IU/day.5 Although we  did not measure
e value of vitamin A in blood, the patient injected more
an 2,100,000 IU/month (which correspond 70.000 IU of vita-
in  A/day) for more  than 4 years, which is compatible with
xicity. Hypercalcemia is a well-known but uncommon com-ceed 10,000 IU/day, and is generally associated with serum
vels of 25-hydroxyvitamin D that are well above 150 ng/mL.8
 this case, 60,000 IU of ergocalciferol were inject monthly
d serum vitamin D was in the upper limit of normal. The
lerable upper level of daily vitamin D intake recently set
 the Institute of Medicine is 4000 IU.8 Vitamin A and D
n act synergistically to cause hypercalcemia. Contrary to
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Table 1 – Laboratory evaluation
Parameter Reference range On admission 48 h One week Two weeks At discharge
Hemoglobin 14.3–18.3 g/dL 14.8 g/dL 13.1 13.6 12.9
Creatinine 0.6–1.2 mg/dL 1.2 3.8 1.92 1.4 0.7
Urea 20–44 mg/dL 52.93 125 84.4 43 36
Lipase 0–75 IU/L 612 456 321 63
Amylase 50–160 IU/L 2500 1430 234 88
Corrected Calcium 8.5–10.5 mg/dL 12.5 12.3 11.1 9.0
Albumin 2.9–5.2 g/dL 3.0 2.5 3.0 2.4
PTH 15–68.3 pg/mL 73.2 70.2 38 35
25-OH-VIT D 30–100 ng/mL 65.1 56.2 69.7
Phosphorus 2.5–4.5 mg/dL 3.8 3.0 3.2 4.0
Triglyceride 50–200 mg/dL 61 185
Fig. 1 – Evolution of physical tone during hospitalization.
what we  were expecting, the patient described here presen-
ted with hypercalcemia and moderated increased serum PTH,
instead of suppression of the activity of this hormone by mul-
tidrug and vitamin abuse. Multifactorial mechanisms may be
involved and some possible explanations are: vitamin A into-
xication may have had a leading role in the development
of hypercalcemia and itself may increase PTH secretion6;
parathyroid overactivity has been described in critical ill-
ness associated with sepsis and renal failure (life-threatening
tertiary hyperparathyroidism).9 Primary hyperparathyroidism
from adenoma or hyperplasia was excluded by negative ima-
ging studies and the restoration of serum calcium and PTH
to normal levels after discontinuation of the drugs. Finally,
in the case reported here there was a peculiar involvement
of the neck and the arms due to self-injection of mineral oil,
more  apparent after the signiﬁcant weight loss observed (more
than 30 kg) by the patient (Fig. 1). Biopsy of the affected skin
revealed multinucleated giant cells and inﬂammatory inﬁltra-
In conclusion, clinicians need to be aware that AAS and
multivitamin abuse can occur with relative frequency and
their use can be surreptitious. The simultaneous occurrence
of nephrocalcinosis, nephrolithiasis, acute kidney injury and
acute pancreatitis may be a clue to the diagnosis of associated
chronic hypercalcemia.
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Calciﬁcaciones  valvulares  en  enfermedad  renal
crónica:¿enfermedad mineral  ósea  o riesgo  cardiovascular
previo? Respuesta
Valvular  calciﬁcations  in  chronic  kidney  disease:  Mineral  and  bone

































gradecemos a Bocanegra et al. su interés sobre nuestro
abajo1.
En sus comentarios sen˜alan que en la sección de Métodos
o son mencionados los valores de fósforo, calcio y PTH de los
acientes con y sin calciﬁcación valvular (CV). El motivo fue
 decisión de incluir en la tabla solo los valores con diferen-
as estadísticamente signiﬁcativas, de ahí que los valores de
sforo, al ser diferentes, se muestran en la tabla 1 del trabajo
riginal. En nuestro estudio las determinaciones de calcio y
H son similares en ambos grupos de pacientes, con y sin
V, y están dentro del rango de recomendación de las KDOQI,
mo se muestra en la tabla 1 del presente manuscrito.
Respecto a su comentario sobre el análisis multivariante de
s factores asociados a la CV, debemos aclarar lo siguiente: se
ectuó un análisis en el que se incluyeron las variables esta-
ísticamente diferentes entre grupos, el fósforo entre ellas, y
mbién otras que pueden estar relacionadas con el proceso
e calciﬁcación: lípidos, proteína C reactiva y también PTH y
lcio, aunque estos omitidos involuntariamente en el texto,or lo que agradecemos a Bocanegra et al. la oportunidad de
ortar esta información. Los resultados del análisis multi-
riante mostraron que la mayor edad y el menor nivel debúmina se asocian de forma independiente con la presencia
e la CV, como ﬁgura en la tabla 3 del trabajo mencionado.
Como sen˜alan Bocanegra et al., nuestro estudio demuestra
ue la presencia de CV es un factor de riesgo independiente de
resentación de eventos y mortalidad cardiovascular, si bien
o distingue los factores implicados en la génesis de la CV, a
cepción de la mayor edad y la albúmina. En nuestro estudio,
 CV no se asoció a alteraciones bioquímicas del metabolismo
seo-mineral medidas en la práctica clínica habitual, al igual
ue en otros estudios2. De la misma  manera, no hubo asocia-
ón con comorbilidades aterogénicas o aterosclerosis estable-
da. Esta asociación no ha sido valorada en la mayoría de los
Tabla 1 – Niveles de calcio y PTH de los pacientes con y
sin presencia de calciﬁcación valvular
Pacientes sin
CV (n = 128)
Pacientes con
CV (n = 128)
p
Calcioa (mg/dl) 9,28 ± 0,86 9,30 ± 0,94 0,88
PTH (pg/ml) 271,3 ± 263,8 234,5 ± 228,9 0,23CV: calciﬁcación valvular; PTH: hormona paratiroidea.
a Calcio corregido para la albúmina.
